Amplia Therapeutics Reappoints Experienced CFO to Support Biotech Growth

Amplia Therapeutics ( (AU:ATX) ) just unveiled an announcement.

Amplia Therapeutics has appointed Hamish George as its Chief Financial Officer, effective 25 February 2026, marking his return to the role after previously serving as CFO from October 2021 and succeeding fellow Bio101 Financial Advisory director Tim Luscombe. The move underscores continuity in financial leadership at the ASX-listed biotech, with management highlighting George’s extensive life sciences finance experience as supportive of Amplia’s ongoing development programs in cancer and fibrosis.

The change in CFO, while not altering Amplia’s strategic direction, is likely to provide stability and specialised financial oversight as the company advances its FAK inhibitor pipeline in competitive oncology and fibrosis markets. For stakeholders, the reappointment of an experienced and previously proven finance chief signals an emphasis on governance, capital management and operational consistency during a critical phase of clinical and corporate development.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

More about Amplia Therapeutics

Amplia Therapeutics Limited is an Australian pharmaceutical company developing a pipeline of focal adhesion kinase inhibitors targeting cancer and fibrosis. The company’s research is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases including idiopathic pulmonary fibrosis, positioning it within the oncology and fibrosis therapeutics market.

Average Trading Volume: 624,214

Technical Sentiment Signal: Sell

Current Market Cap: A$62.85M

For a thorough assessment of ATX stock, go to TipRanks’ Stock Analysis page.